Matsuo et al., 1996 - Google Patents
Lamotrigine high‐dose tolerability and safety in patients with epilepsy: a double‐blind, placebo‐controlled, eleven‐week studyMatsuo et al., 1996
- Document ID
- 14965171020534641672
- Author
- Matsuo F
- Gay P
- Madsen J
- Tolman K
- Rollins D
- Risner M
- Lai A
- Publication year
- Publication venue
- Epilepsia
External Links
Snippet
Purpose: This study was undertaken to evaluate the dose tolerability and safety of a chronic ascending twice‐daily (bid) dosage regimen of 700 mg/day larnotrigine (LTG) and to include determination of the LTG pharmacokinetic profile at doses 500 mg/day in patients receiving …
- 239000000902 placebo 0 title abstract description 17
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ben‐Menachem et al. | Double‐blind, placebo‐controlled trial of topiramate as add‐on therapy in patients with refractory partial seizures | |
| DE69735581T2 (en) | DOSAGE FOR A DELAYED AND INCREASING INGREDIENTS | |
| DE69224080T2 (en) | USE OF NSAID FOR THE TREATMENT OF DEMENTIA | |
| EP0326034B1 (en) | Combination for the treatment of nervous cells and fibers illnesses and disorders | |
| Richens et al. | Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial | |
| EP1037648A2 (en) | The use of erythropoietin and iron preparations for producing pharmaceutical combination preparations for treating rheumatic diseases | |
| DE69731840T2 (en) | Pharmaceutical compositions containing CS-866 and insulin resistance enhancing agents and their use for the treatment of arteriosclerosis and xanthoma | |
| Matsuo et al. | Lamotrigine high‐dose tolerability and safety in patients with epilepsy: a double‐blind, placebo‐controlled, eleven‐week study | |
| Radulovic et al. | Lack of interaction of gabapentin with carbamazepine or valproate | |
| Horwitz et al. | Relation of abnormal folate metabolism to neuropathy developing during anticonvulsant drug therapy | |
| Mikati et al. | Double‐blind randomized study comparing brand‐name and generic phenytoin monotherapy | |
| Garnett et al. | Pharmacokinetic evaluation of twice‐daily extended‐release carbamazepine (CBZ) and four‐times‐daily immediate‐release CBZ in patients with epilepsy | |
| DE69605531T2 (en) | Carnitine derivative as a medicine for the treatment of arteriosclerosis obliterans | |
| DE3390116C2 (en) | Improved caffeine-containing analgesic and anti-inflammatory agents | |
| DE19737348A1 (en) | New pharmaceutical composition | |
| Vitale et al. | Oral penicillamine therapy for chronic lead poisoning in children | |
| DE60009145T2 (en) | COMPOSITION OF GINSENG AND GINKGO TO IMPROVE COGNITIVE ASSETS | |
| EP0398165B1 (en) | Combination preparations containing rifampicin and thioacetazone and eventually isoniazide or ethambutol as active agents | |
| EP0215956A1 (en) | Composition for treating skin disease | |
| DE4206422C2 (en) | Medicines for the prophylaxis and treatment of neurological and psychiatric damage caused by alcohol abuse | |
| EP0331014A2 (en) | Use of ACE inhibitors in diabetes prophylaxis | |
| DE3875107T2 (en) | USE OF FRUCTOSE 1,6-DIPHOSPHATE FOR TREATING ACUTE ALCOHOL POISONING AND CHRONIC ALCOHOLISM AND RELATED PHARMACEUTICAL COMPOSITIONS. | |
| DE19726871C1 (en) | Synergistic compositions for the selective control of tumor tissue | |
| Luther et al. | The effects of terazosin and methyclothiazide on blood pressure and serum lipids | |
| DE68909304T2 (en) | Amino acids for the treatment of neurodegenerative disorders. |